Kezar Life Sciences, Inc. – NASDAQ:KZR

Add to watchlist

$3.871

-2.76

-41.71%

Market closed

Open in about 9 hours

+942.55%

month

+942.55%

quarter

+586.38%

year

Market Cap	46.41M
Enterprise value	141.14M

P/E	-2.45
EV/Sales	N/A
EV/EBITDA	-2.13
Price/Sales	N/A
Price/Book	0.59
PEG ratio	-0.84
EPS	-1.40

Revenue	N/A
EBITDA	-100.77M
Income	-101.32M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kezar Life Sciences Stock Forecast

M Q Y

Last Year

Potential upside: 132.52%

Analysts Price target
Financials & Ratios estimates

Kezar Life Sciences, Inc. (NASDAQ:KZR): Profit margin
Jun 2023	0	-24.30M
Sep 2023	7M	-23.10M	-330.04%
Dec 2023	-5.42M	-32.25M	594.33%
Mar 2024	0	-21.65M

Kezar Life Sciences, Inc. (NASDAQ:KZR): Debt to assets
Jun 2023	263379000	31.10M	11.81%
Sep 2023	249326000	33.33M	13.37%
Dec 2023	221235000	33.66M	15.22%
Mar 2024	199130000	30.00M	15.07%

Kezar Life Sciences, Inc. (NASDAQ:KZR): Cash Flow
Jun 2023	-21.6M	13.20M	382K
Sep 2023	-20.20M	18.57M	43K
Dec 2023	-18.98M	27.87M	59K
Mar 2024	-22.86M	20.40M	0

Kezar Life Sciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kezar Life Sciences, Inc. (NASDAQ:KZR): Employee count
Aug 2023	84
Sep 2023	84
Oct 2023	84
Nov 2023	84
Dec 2023	84
Jan 2024	84
Feb 2024	84
Mar 2024	58
Apr 2024	58
May 2024	58
Jun 2024	58
Jul 2024	58

Kezar Life Sciences
Hedge Funds Holdings Q1 2022

82.61% +5.22%

of KZR is owned by hedge funds

116 +10

hedge funds hold KZR stock

43.58M +3.30M

shares is hold by hedge funds

KZR hedge funds holdings changes

Kezar Life Sciences
Insider Trading

Kezar Life Sciences, Inc. (NASDAQ:KZR): Insider trades (number of shares)
Period	Buy	Sel
Mar 2022	80000	0
Oct 2022	0	32312
Dec 2022	0	25000
Jan 2023	0	328747
Feb 2023	0	155000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	20 Jul 2023	KIRK CHRISTOPHER J. director	Common Stock	48,950	$0.9	$44,055
Option	20 Jul 2023	KIRK CHRISTOPHER J. director	Employee Stock Option (right to buy)	48,950	$0.9	$44,055
Sale	6 Feb 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	40,000	$6.88	$275,320
Sale	3 Feb 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	25,000	$7.15	$178,650
Sale	2 Feb 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	50,000	$7.19	$359,500
Sale	1 Feb 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	40,000	$6.95	$278,000
Sale	31 Jan 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	30,000	$7.08	$212,400
Sale	30 Jan 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	30,000	$6.91	$207,300
Sale	25 Jan 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	50,000	$6.85	$342,500
Sale	24 Jan 2023	MORNINGSIDE VENTURE INVESTMENTS LTD 10 percent owner 10 percent owner	Common Stock	80,000	$6.98	$558,400

KZR insider trading transactions

Kezar Life Sciences
Earnings Call Transcripts

Quarter	Transcript
Q2 2020 9 Aug 2020	Q2 2020 Earnings Call Transcript

KZR earnings call transcripts

Kezar Life Sciences
Executives

Insider	Age	Compensation
Mr. John Franklin Fowler (1972) Co-Founder, Chief Executive Officer & Director	53	$801,780
Dr. Noreen Roth Henig (1965) Chief Medical Officer	60	$616,170
Dr. Christopher J. Kirk (1972) Co-Founder, Pres, Chief Scientific Officer & Director	53	$590,160

Kezar Life Sciences
Latest News

Tuesday, 12 November 2024
16:01	Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update	businesswire.com
Tuesday, 5 November 2024
10:58	Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)	businesswire.com
Monday, 28 October 2024
08:30	Kezar Life Sciences Announces 1-for-10 Reverse Stock Split	businesswire.com
Thursday, 17 October 2024
08:35	Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan	businesswire.com
08:30	Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update	businesswire.com
Tuesday, 15 October 2024
13:00	What Makes Kezar Life Sciences (KZR) a New Buy Stock	zacks.com
Thursday, 10 October 2024
08:30	Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal	businesswire.com
Friday, 4 October 2024
17:11	US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial	reuters.com
17:00	Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis	businesswire.com
Monday, 30 September 2024
08:46	Kezar Life Sciences halts mid-stage trial for lupus treatment	reuters.com
08:30	Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients	businesswire.com
Wednesday, 10 July 2024
16:01	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	businesswire.com
Friday, 7 June 2024
17:59	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 29 May 2024
16:01	Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference	businesswire.com
Monday, 6 May 2024
16:05	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	businesswire.com
Monday, 8 April 2024
16:01	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 27 March 2024
16:30	From Pennies to Fortunes: 3 Stocks Set to Make Millionaires	investorplace.com
Saturday, 16 March 2024
06:56	Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026	InvestorPlace
Sunday, 25 February 2024
14:12	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond	InvestorPlace
Friday, 2 February 2024
05:37	3 Penny Stocks Poised for an Unbelievable 1,000% Jump	InvestorPlace
Monday, 18 December 2023
08:51	Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth	InvestorPlace
Wednesday, 4 October 2023
11:17	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce	Zacks Investment Research
Sunday, 24 September 2023
22:33	Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement	Seeking Alpha
Wednesday, 4 January 2023
16:01	Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference	Business Wire
Wednesday, 16 November 2022
01:23	Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold	Seeking Alpha
Friday, 14 October 2022
07:00	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual Meeting	Business Wire
Thursday, 29 September 2022
16:05	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022	Business Wire
Thursday, 1 September 2022
07:00	Kezar Life Sciences to Participate in Three Upcoming Investor Conferences	Business Wire
Wednesday, 27 July 2022
13:45	Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case	Seeking Alpha
Thursday, 7 July 2022
16:30	Kezar Life Sciences to Present at the William Blair Biotech Focus Conference	Business Wire

Frequently Asked Questions (FAQ)

What's the price of Kezar Life Sciences stock today?

One share of Kezar Life Sciences stock can currently be purchased for approximately $3.87.
When is Kezar Life Sciences's next earnings date?

Unfortunately, Kezar Life Sciences's (KZR) next earnings date is currently unknown.
Does Kezar Life Sciences pay dividends?

No, Kezar Life Sciences does not pay dividends.
How much money does Kezar Life Sciences make?

Kezar Life Sciences has a market capitalization of 46.41M.
What is Kezar Life Sciences's stock symbol?

Kezar Life Sciences, Inc. is traded on the NASDAQ under the ticker symbol "KZR".
What is Kezar Life Sciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kezar Life Sciences?

Shares of Kezar Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kezar Life Sciences's key executives?
Kezar Life Sciences's management team includes the following people:
- Mr. John Franklin Fowler Co-Founder, Chief Executive Officer & Director(age: 53, pay: $801,780)
- Dr. Noreen Roth Henig Chief Medical Officer(age: 60, pay: $616,170)
- Dr. Christopher J. Kirk Co-Founder, Pres, Chief Scientific Officer & Director(age: 53, pay: $590,160)
Is Kezar Life Sciences founder-led company?

Yes, Kezar Life Sciences is a company led by its founders Mr. John Franklin Fowler and Dr. Christopher J. Kirk.
How many employees does Kezar Life Sciences have?

As Jul 2024, Kezar Life Sciences employs 58 workers.
When Kezar Life Sciences went public?

Kezar Life Sciences, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
What is Kezar Life Sciences's official website?

The official website for Kezar Life Sciences is kezarlifesciences.com.
Where are Kezar Life Sciences's headquarters?

Kezar Life Sciences is headquartered at 4000 Shoreline Court, South San Francisco, CA.
How can i contact Kezar Life Sciences?

Kezar Life Sciences's mailing address is 4000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +65 08225600.
What is Kezar Life Sciences stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Kezar Life Sciences in the last 12 months, the avarage price target is $9. The average price target represents a 132.52% change from the last price of $3.87.

Kezar Life Sciences, Inc.

kezarlifesciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

+65 08225600

4000 Shoreline Court
South San Francisco, CA 94080

CIK: 0001645666
ISIN: US49372L1008
CUSIP: 49372L100